Please ensure Javascript is enabled for purposes of website accessibility
David Haen

David Haen


Recent articles


Is Pfizer a Great Dividend Stock?

A strategic transaction this year will give investors two shots to earn dividends.


Now’s the Time to Buy These 3 Stocks

These drug developers will give your portfolio a boost.


3 Top Pharma Stocks to Buy Right Now

Promising new drugs will drive these companies' stocks skyward.


Should You Own This Sleeper Biotech Stock?

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.


Where Will Adaptimmune Be in 5 Years?

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.


Will GenMark Diagnostics' Stock Keep Rising?

A coronavirus diagnostic test is fueling this biotech's revenue for 2020.


This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Third-quarter results from a COVID-19 trial could send this stock soaring.


Is There A Safer Way to Invest in a Coronavirus Vaccine?

Size may matter in the long run.


Is Axsome Therapeutics a Screaming Buy?

Two positive late-stage clinical trials may just be the beginning.


If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now

Not all IPO returns are equal.


Should You Buy Global Blood Therapeutics Before This Week's Earnings?

On Wednesday, investors will learn the progress of its sickle cell disease drug launch.


AstraZeneca Notches Win with Prostate Cancer Drug

New clinical trial results may lead to a label expansion this quarter for Lynparza, and huge revenue growth for the drug.


Did Merck Just Receive a Gift From the FDA?

A new, more convenient dosing schedule favors Keytruda.


Better Buy: Illumina vs. Adaptive Biotechnologies

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.


Should You Buy Stock Now in This New Coronavirus Drug Developer?

This company's repurposed cancer drug might help patients with severe COVID-19.


Will Last Week's Biotech IPO Outperform in a Recession?

This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.


Myovant Squares Off with AbbVie On Endometriosis Treatment

With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.


Better Buy: AnaptysBio vs. Exelixis

Key clinical trial results this quarter will determine the better buy.


These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

These companies just raised significant cash to advance promising drug pipelines.


Could CVS Health Be a Millionaire-Maker Stock?

Investors seek to capitalize on one of the broadest-reaching companies in healthcare.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.